ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+22.44%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$102M
AUM Growth
+$102M
(+27%)
Cap. Flow
+$5.97M
Cap. Flow
% of AUM
5.87%
Top 10 Holdings %
Top 10 Hldgs %
56.24%
Holding
49
New
13
Increased
10
Reduced
13
Closed
13
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$9.04M |
| 2 |
Acadia Healthcare
ACHC
|
$5.25M |
| 3 |
Exact Sciences
EXAS
|
$3.54M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$3.29M |
| 5 |
AnaptysBio
ANAB
|
$2.89M |
Top Sells
| 1 |
Natera
NTRA
|
$3.89M |
| 2 |
PTC Therapeutics
PTCT
|
$3.86M |
| 3 |
Sarepta Therapeutics
SRPT
|
$2.36M |
| 4 |
KALA BIO
KALA
|
$2.13M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$1.94M |
Sector Composition
| 1 | Healthcare | 89.76% |
| 2 | Technology | 0.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OPTN
1
DELISTED
OptiNose
OPTN
| $9.4M | 9.24% | 335,826 -3,099 | -0.9% | -$86.7K |
|
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $9.04M | 8.89% | +53,208 | New | +$9.04M |
|
|
3
PTC Therapeutics
PTCT
$3.92B
| $6.92M | 6.8% | 205,031 -114,413 | -36% | -$3.86M |
|
|
4
Acadia Healthcare
ACHC
$2.12B
| $5.25M | 5.16% | +128,240 | New | +$5.25M |
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $5.1M | 5.02% | 29,625 -1,679 | -5% | -$289K |
|
|
6
Exact Sciences
EXAS
$8.98B
| $5.08M | 4.99% | 84,937 +59,134 | +229% | +$3.54M |
|
7
Centene
CNC
$14.3B
| $4.81M | 4.73% | 39,058 -9,218 | -19% | -$1.14M |
|
8
Insmed
INSM
$28.8B
| $4.7M | 4.62% | 198,801 +36,616 | +23% | +$866K |
|
9
UnitedHealth
UNH
$281B
| $3.55M | 3.49% | 14,452 -3,066 | -18% | -$752K |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.36M | 3.3% | 49,756 -19,920 | -29% | -$1.35M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.29M | 3.23% | +87,116 | New | +$3.29M |
|
|
12
AnaptysBio
ANAB
$569M
| $2.89M | 2.84% | +40,718 | New | +$2.89M |
|
|
VRAY
13
DELISTED
ViewRay, Inc.
VRAY
| $2.7M | 2.66% | +390,568 | New | +$2.7M |
|
14
Quest Diagnostics
DGX
$20.3B
| $2.7M | 2.66% | 24,575 -7,654 | -24% | -$842K |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $2.64M | 2.6% | 26,910 -2,915 | -10% | -$286K |
|
16
Heron Therapeutics
HRTX
$207M
| $2.58M | 2.54% | 66,488 -10,858 | -14% | -$422K |
|
|
17
Natera
NTRA
$23.1B
| $2.24M | 2.2% | 118,869 -206,660 | -63% | -$3.89M |
|
|
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.23M | 2.19% | 49,355 +27,355 | +124% | +$1.24M |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.18M | 2.14% | +25,918 | New | +$2.18M |
|
20
Amicus Therapeutics
FOLD
$2.34B
| $2.06M | 2.03% | 132,160 -62,585 | -32% | -$977K |
|
21
Opko Health
OPK
$1.1B
| $1.91M | 1.88% | 406,526 +265,482 | +188% | +$1.25M |
|
22
Bio-Rad Laboratories Class A
BIO
$8.06B
| $1.71M | 1.68% | 5,918 +1,407 | +31% | +$406K |
|
23
Perrigo
PRGO
$3.27B
| $1.71M | 1.68% | 23,389 +10,642 | +83% | +$776K |
|
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $1.49M | 1.46% | 11,249 -17,884 | -61% | -$2.36M |
|
25
Viking Therapeutics
VKTX
$3.04B
| $1.46M | 1.44% | +154,207 | New | +$1.46M |
|